← Back to guidelines
Allergy & Immunology2 papers

Rhesus isoimmunization due to anti-c

Last edited: 4/15/2026

Overview

Rhesus isoimmunization due to anti-C antibodies occurs when Rh-negative individuals produce antibodies against the C antigen following exposure to Rh-positive blood or other Rh-positive substances, potentially leading to hemolytic disease of the newborn (HDN) in subsequent pregnancies.

Diagnosis

  • Detection of anti-C antibodies via serological testing (indirect antiglobulin test, DAT/IAT) 1.
  • Confirmatory tests may include elution and identification of specific antibodies 1.
  • Management

  • First-line: Avoidance of Rh-positive blood exposure through careful blood transfusion protocols and Rh immunoglobulin (RhIG) prophylaxis for Rh-negative women carrying Rh-positive fetuses 1.
  • Adjunctive: Monitoring maternal antibody levels and fetal status through serial ultrasounds and amniocentesis if indicated 1.
  • Special Populations

  • Pregnancy: RhIG administration at 28 weeks gestation and within 72 hours postpartum for Rh-negative mothers carrying Rh-positive fetuses to prevent maternal sensitization 1.
  • Pediatrics: Not specifically addressed in provided abstracts.
  • Elderly: Not specifically addressed in provided abstracts.
  • Comorbidities: Management strategies for comorbidities remain standard care with additional vigilance for Rh-incompatibility issues 1.
  • Key Recommendations

  • Administer Rh immunoglobulin prophylaxis to Rh-negative pregnant women carrying Rh-positive fetuses to prevent maternal sensitization and subsequent HDN 1 (Evidence: Strong).
  • Implement rigorous blood transfusion protocols to minimize Rh-positive blood exposure in Rh-negative individuals 1 (Evidence: Strong).
  • Regular monitoring of maternal anti-C antibody levels and fetal well-being in at-risk pregnancies is recommended 1 (Evidence: Moderate).
  • References

    1 Rup B, Pallardy M, Sikkema D, Albert T, Allez M, Broet P et al.. Standardizing terms, definitions and concepts for describing and interpreting unwanted immunogenicity of biopharmaceuticals: recommendations of the Innovative Medicines Initiative ABIRISK consortium. Clinical and experimental immunology 2015. link 2 Kitagawa T, Tanimori H, Yoshida K, Miura T, Fujiwara K. High dimensional structure of the antigen-binding site of anti-viomycin immunoglobulin analyzed by enzyme immunoassay. Journal of biochemistry 1982. link

    Original source

    1. [1]
    2. [2]
      High dimensional structure of the antigen-binding site of anti-viomycin immunoglobulin analyzed by enzyme immunoassay.Kitagawa T, Tanimori H, Yoshida K, Miura T, Fujiwara K Journal of biochemistry (1982)

    HemoChat

    by SPINAI

    Evidence-based clinical decision support powered by SNOMED-CT, Neo4j GraphRAG, and NASS/AO/NICE guidelines.

    ⚕ For clinical reference only. Not a substitute for professional judgment.

    © 2026 HemoChat. All rights reserved.
    Research·Pricing·Privacy & Terms·Refund·SNOMED-CT · NASS · AO Spine · NICE · GraphRAG